Alector Framtida tillväxt

Future kriterier kontrolleras 5/6

Alector förväntas öka intäkter och intäkter med 38.8% respektive 40.2% per år. EPS förväntas tillväxt med 43.3% per år. Avkastningen på eget kapital förväntas bli -150.9% om 3 år.

Viktig information

38.8%

Tillväxttakt i vinsten

43.29%

Tillväxttakt för EPS

Biotechs vinsttillväxt	23.7%
Intäkternas tillväxttakt	40.2%
Framtida avkastning på eget kapital	-150.93%
Bevakning av analytiker	Good
Senast uppdaterad	13 May 2025

Senaste uppdateringarna om framtida tillväxt

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

Recent updates

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 05

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Apr 03 Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 21

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Mar 13

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Dec 23

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Nov 28

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:ALEC - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
Datum	Intäkter	Intäkter	Fritt kassaflöde	Kassaflöde från rörelsen	Genomsnittligt Antal analytiker
12/31/2027	96	-125	-131	-93	5
12/31/2026	59	-161	-122	-108	7
12/31/2025	12	-178	-101	-91	7
3/31/2025	88	-123	-230	-229	N/A
12/31/2024	101	-119	-231	-230	N/A
9/30/2024	62	-158	-222	-221	N/A
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	-102	-88	N/A
6/30/2019	28	-76	-94	-82	N/A
3/31/2019	28	-62	-84	-81	N/A
12/31/2018	28	-52	N/A	127	N/A
9/30/2018	22	-45	N/A	143	N/A
6/30/2018	15	-39	N/A	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: ALEC förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 2.9% ).

Resultat vs marknad: ALEC förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: ALEC förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: ALEC s intäkter ( 40.2% per år) förväntas växa snabbare än US marknaden ( 8.6% per år).

Hög tillväxtintäkter: ALEC s intäkter ( 40.2% per år) förutspås växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: ALEC förväntas bli olönsam om 3 år.

Upptäck tillväxtföretag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/05/22 19:54
Aktiekurs vid dagens slut	2025/05/22 00:00
Intäkter	2025/03/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Alector, Inc. bevakas av 15 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Alec Stranahan	BofA Global Research
Thomas Shrader	BTIG
Pete Stavropoulos	Cantor Fitzgerald & Co.

Alector Framtida tillväxt

Future kriterier kontrolleras 5/6

Viktig information

Senaste uppdateringarna om framtida tillväxt

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Recent updates

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Alector, Inc., Annual General Meeting, Jun 11, 2025

New minor risk - Share price stability

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

New minor risk - Market cap size

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Alector Provides Executive Leadership Update

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Co-Founder recently sold US$59k worth of stock

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Co-Founder notifies of intention to sell stock

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Insufficient new directors

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Price target decreased by 22% to US$6.33

Co-Founder recently sold US$131k worth of stock

Co-Founder notifies of intention to sell stock

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Alector: Bleak Prospects After Alzheimer's Failure

Price target decreased by 37% to US$10.28

Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has filed a Follow-on Equity Offering.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)